NCT04790942 is a Phase 4 clinical trial of berberine hydrochloride in Hypertension, sponsored by Jun Tao.

Who is sponsoring NCT04790942?

NCT04790942 is sponsored by Jun Tao.

What drugs are being tested in NCT04790942?

Interventions in NCT04790942: berberine hydrochloride, lifestyle intervention group.

What condition does NCT04790942 study?

NCT04790942 studies Hypertension, Endothelial Dysfunction, Blood Pressure.

Is NCT04790942 still recruiting?

NCT04790942 is currently status unknown. Last updated 10 March 2021.

Last reviewed 2021-03-10 · How we verify

NCT04790942

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Berberine Hydrochloride on Blood Pressure and Vascular Endothelial Function in Patients With Hypertension

Status unknown Phase 4 Last updated 10 March 2021

What this trial tests

Phase 4 trial testing berberine hydrochloride in Hypertension in 30 participants. Status unknown.

Timeline

22 October 2020

Primary endpoint
22 February 2022

22 May 2022

Quick facts

Lead sponsor	Jun Tao
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	30
Start date	22 October 2020
Primary completion	22 February 2022
Estimated completion	22 May 2022
Sites	1 location across China

Drugs / interventions tested

berberine hydrochloride — full drug profile →
lifestyle intervention group

Conditions studied

Hypertension — all drugs for Hypertension →
Endothelial Dysfunction — all drugs for Endothelial Dysfunction →
Blood Pressure — all drugs for Blood Pressure →

Sponsor

Jun Tao

Who can join

Adults 18 to 75, any sex, with Hypertension or Endothelial Dysfunction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Hypertension is a progressive cardiovascular syndrome caused by multiple causes, which can lead to changes in the function and structure of the heart and blood vessels. It is the leading risk factor of cardiovascular disease. Berberine (BBR) hydrochloride is an isoquinoline alkaloid (chemical formula: C20H18NO4) extracted from traditional Chinese herb Coptis chinensis. It has been widely used to treat diarrhea and enteritis for hundreds of years in China. BBR has extremely high clinical application value. It is an over-the-counter drug with low price, good safety and few adverse reactions in China. We found that Berberine (BBR) hydrochloride tablets have a hypotensive effect in clinical practice. However, there are few clinical studies on the treatment of hypertensive patients with BBR tablets. In addition, the clinical dosage of BBR tablets is not uniform, and its molecular mechanism is still unclear. In order to further evaluate the clinical efficacy of BBR in reducing blood pressure and improving vascular endothelial injury, we carried out this clinical trial of drug intervention for hypertensive population. After signed the informed consent, the subjects are assigned to the lifestyle intervention group (CON) and berberine hydrochloride group (BBR). The berberine hydrochloride group (BBR) take berberine hydrochloride tablets (0.4g, 3 times/day, 3 months) . We will follow up blood pressure and vascular endothelial function in 1 month and 3 months after taking the medicine.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Effects of Berberine on Atherosclerosis.
Rui R, Yang H, Liu Y, Zhou Y, et al · · 2021 · cited 36× · PMID 34899318 · DOI 10.3389/fphar.2021.764175
NADPH-oxidases as potential pharmacological targets for thrombosis and depression comorbidity.
Amadio P, Sandrini L, Zarà M, Barbieri SS, et al · · 2024 · cited 16× · PMID 38310682 · DOI 10.1016/j.redox.2024.103060

Verify or expand the search:

Other recruiting trials for Hypertension

Currently open trials in the same condition.

NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A · NA · recruiting
NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S · recruiting
NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia · Phase 2 · recruiting
NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension · NA · recruiting

Other Jun Tao trials

Trials by the same sponsor.

NCT06445244 — α-ketoglutarate in Patients With Hypertension · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04790942 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jun Tao
Last refreshed: 10 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04790942.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing